临床生物标记市场:全球和区域分析 - 按产品细分、按临床领域、按技术、按最终用户、按地区 - 分析和预测,2023-2033 年
市场调查报告书
商品编码
1419699

临床生物标记市场:全球和区域分析 - 按产品细分、按临床领域、按技术、按最终用户、按地区 - 分析和预测,2023-2033 年

Clinical Biomarkers Market - A Global and Regional Analysis: Focus on Offering, Clinical Area, Technology, End User, and Region - Analysis and Forecast, 2023-2033

出版日期: | 出版商: BIS Research | 英文 255 Pages | 商品交期: 1-5个工作天内

价格

全球临床生物标记市场规模预计将从2023年的248亿美元成长到2033年的532亿美元,预测期内复合年增长率为7.93%。

主要市场统计数据
预测期 2023-2033
2023年评估 248亿美元
2033年预测 532亿美元
复合年增长率 7.93%

由于产品和服务用途的扩大、主要企业倡议的增加以及政府对临床生物标誌物的倡议的增加,全球临床生物标誌物市场预计将出现高速增长。市场成长的推动因素是医疗保健公司为满足行业需求而持续进行的大规模投资,以及关键终端用户对药物研发发现和开发、疾病风险评估等的日益采用,这是主要的支撑因素。药物研发包括快速发展的检测方法和系统,例如癌症生物标记、心臟生物标记和感染疾病生物标记。

从产品细分来看,2022年产品细分市场占有率为76.59%。此外,从临床领域来看,癌症生物标记部分预计将在预测期内显示出最高的增长。此外,从技术角度来看,次世代定序(NGS)领域预计到 2022 年将以 31.55% 的份额引领市场,并且在预测期内也呈现出最高的成长。随着新定序技术的开发和改进,NGS 在过去十年中越来越多地应用于癌症基因组学研究。

本报告调查了全球临床生物标记市场,并提供了市场概况、市场成长的各种影响因素分析、专利趋势、法律制度、市场规模趋势和预测、主要国家和主要企业的详细分析。其他信息。

目录

执行摘要

第一章 市场

第二章 市场范围

第三章调查方法

第四章市场概况

  • 精准医学中的临床生物标记方法
  • 临床生物标记的潜在市场规模
  • COVID-19 对全球临床生物标记市场的影响
  • 市场趋势

第五章业界考察

  • 法律规范
  • 专利分析
  • 竞争指数(未满足的需求和创新)
  • 厂商的问题

第六章竞争考察

  • 经营策略
  • 经营策略
  • 供应链分析
  • 价格分析
  • 市场占有率分析(按产品製造商)
  • 市场占有率分析(按服务供应商)

第七章市场动态

  • 概述
  • 影响分析
  • 市场驱动因素
  • 市场问题
  • 市场机会

第八章全球临床生物标记市场:按报价细分

  • 概述
  • 产品
    • 功效生物标记
    • 安全生物标记
    • 检验生物标记
  • 服务
    • 基因生物标誌物服务
    • 组织生物标记服务
    • 手机服务
    • 蛋白质体学服务

第九章全球临床生物标记市场:依技术分类

  • 概述
  • 下一代定序(NGS)
  • 聚合酶炼式反应 (PCR)
  • 免疫组织化学 (IHC)
  • 酵素免疫分析法测定法 (ELISA)
  • 其他的

第10章全球临床生物标记市场:依临床领域

  • 概述
  • 癌症生物标记
    • 乳癌生物标记
    • 肺癌生物标记
    • 大肠癌症生物标记
    • 前列腺癌症生物标记
    • 其他的
  • 心臟生物标记
  • 神经系统生物标记
  • 感染疾病生物标记
  • 非侵入性产前检测
  • 免疫生物标记
  • 其他的

第十一章全球临床生物标记市场:依最终用户分类

  • 概述
    • 受託研究机构(CRO)
    • 研究/学术实验室
    • 诊断中心
    • 生物製药和生物技术公司
    • 其他的

第十二章 区域

  • 概述
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 其他地区

第十三章市场-公司简介

  • 概述
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ALCEN
  • Arsenal Capital Partners
  • Azenta Life Sciences
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • BGI
  • Broad Institute
  • Charles River Laboratories
  • Caris Life Sciences
  • CENTOGENE NV
  • Discovery Life Sciences (DLS)
  • Enzo Biochem Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • Novogene Co., Ltd.
  • Personalis Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Q2. Solutions
  • Thermo Fisher Scientific Inc.
Product Code: BHP0826SC

“The Global Clinical Biomarkers Market Expected to Reach $53.20 Billion by 2033.”

Introduction of Clinical Biomarkers Market

The global clinical biomarkers market was valued at $24.80 billion in 2023 and is expected to reach $53.20 billion by 2033, growing at a CAGR of 7.93% between 2023 and 2033. The term clinical biomarkers refers to the quantifiable biological parameter that facilitates the understanding of the progression and early diagnosis of a disease. Clinical biomarkers specifically refer to molecular biomarkers that provide new targets for disease characterization, drug discovery, and development. The report focuses on the manufacturers of different types of tests based on biomarkers, namely prognostic, predictive, and diagnostic biomarkers, as well as services.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$24.80 Billion
2033 Forecast$53.20 Billion
CAGR7.93%

Market Introduction

As per BIS Research, the global clinical biomarkers market includes manufacturers and service providers offering proprietary biomarkers testing products and services for clinical diagnostics and research purposes. The study considers tests based on various technologies for different underlying applications in oncology and non-oncology diseases to detect biomarkers. However, the report does not cover instruments and software.

Industrial Impact

The global clinical biomarkers market is expected to witness high growth, attributed to the growing usage of products and services, the increasing key player initiatives, and the rising government initiatives in clinical biomarkers. The continued significant investments by healthcare companies to meet industry demand and the growing adoption of drug discovery and development, disease risk assessment, and others among major end users are the major factors propelling the growth of the global clinical biomarkers market. Drug discovery encompasses a rapidly evolving range of assays and systems that facilitate cancer biomarkers, cardiac biomarkers, infectious diseases, and others. Infectious diseases also offer prognostic assessments for a wide range of diseases, as well as assistance with treatment selection and monitoring of drug treatment efficacy.

Market Segmentation:

Segmentation 1: by Offering

  • Product
    • Efficacy Biomarker
    • Safety Biomarker
    • Validation Biomarker
  • Service
    • Genomic Biomarker Service
    • Tissue Biomarker Service
    • Cell Service
    • Proteomics Service

Product Segment to Dominate the Clinical Biomarkers Market (by Offering)

Based on product, the global clinical biomarkers market was led by the product segment, with a 76.59% share in 2022. The report focuses on the manufacturers of different types of biomarkers, namely, prognostic, predictive, and diagnostic biomarkers. Acknowledging the future potential for massive growth in demand for biomarker-based assays, several biotechnology and life science companies, such as Illumina, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche Ltd, have invested substantially to aid further developments in clinical biomarkers market.

Segmentation 2: by Clinical Area

  • Cancer Biomarkers
  • Cardiac Biomarkers
  • Neurological Biomarkers
  • Infectious Disease
  • Immunological Biomarkers
  • Non-Invasive Prenatal Testing
  • Other Clinical Areas

Cancer Biomarkers to Witness the Highest Growth between 2023 and 2033

Cancer biomarkers are the biomolecules or the processes observed during the presence of the tumor. These biomolecules could be found in blood, serum, or any other body fluid, indicating the presence of any abnormal process. These biomarkers could be in the form of genetic biomarkers, protein biomarkers, and glycoproteins that are used for the diagnosis or prognosis of a tumor. A few of the biomarkers that have been diagnosed for the development of any diagnostic assay are BRCA1/BRCA2 and EGFR for breast cancer, SSC and TPA for lung cancer, and PSA for prostate cancer.

Segmentation 3: by Technology

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Other Technologies

Next-Generation Sequencing (NGS) to Witness the Highest Growth between 2023 and 2033

Based on technology, the clinical biomarkers market was led by next-generation sequencing, with a 31.55% share in 2022. Next-generation sequencing (NGS) has been increasingly used in cancer genomics research over the last decade (from 2010 to the present) as new sequencing technology has been developed and improved. NGS is a modern and alternative technique that allows clinicians to evaluate several genes of malignancy at the same time. Material from a patient's tumor that has been biopsied or surgically excised can be used for next-generation sequencing.

Segmentation 4: by End User

  • Contract Research Organizations (CROs)
  • Research and Academic Laboratories
  • Biopharmaceutical and Biotech Companies
  • Diagnostic Centers
  • Other End Users

Contract Research Organization (CRO) to Witness the Highest Growth between 2023 and 2033

Contract research organizations (CROs) primarily use biomarker testing services for purposes related to bioanalysis in support of the pharmaceutical and biotechnology industry as well as research and academic institutions. Also, research and academic institutions are outsourcing identification and sequencing projects to CROs in an attempt to cut down on research costs. As a result, CROs form a considerable part of the end users in the clinical biomarkers market.

Segmentation 5: by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • South Korea
    • Australia
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Rest-of-the-World

Recent Developments in the Global Clinical Biomarkers Market

  • In August 2023, Quest Diagnostics launched the AD-Detect test for Alzheimer's disease in the U.S., offering consumers the first opportunity to acquire and evaluate a blood-based biomarker test for assessing the potential risks of developing AD.
  • In September 2023, Becton, Dickinson and Company partnered with Navigate BioPharma Services, Inc. to develop and commercialize flow cytometry-based companion diagnostics and clinical decision tools. The collaboration combined Navigate BioPharma's expertise in biomarker assay design for clinical trials with BD's extensive portfolio of flow cytometry instruments, reagents, software, and in vitro diagnostics (IVD) development services.
  • In November 2023, Abbott Laboratories's Alinity i Lab-Based Blood Test was cleared by the FDA. The product is used to assess mild traumatic brain injury (TBI) or concussion in individuals using two biomarkers.
  • In November 2023, Illumina Inc., a leader in DNA sequencing and array-based technologies, launched the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), a research assay designed for noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood. It is tailored for situations where tissue testing is unavailable or as a complement to tissue-based testing.
  • In May 2023, Thermo Fisher Scientific Inc. declared that its BRAHMS PlGF plus KRYPTOR and BRAHMS sFlt-1 KRYPTOR biomarker immunoassays had received FDA clearance for assessing and managing the risk of preeclampsia.

Demand - Drivers, Challenges, and Opportunities

Market Demand Drivers:

Growing Demand for Clinical Biomarker Products: Due to the ever-rising cancer cases, the need for better products is becoming more evident. Several key players are aligning their technologies as per the market requirements to provide technologically advanced products and services by adopting inorganic strategies such as product launches. Globally, there has been a significant increase in the number of people suffering from different types of cancer. Incidence rates of cancer continue to increase, primarily owing to high-fidelity diagnostic and screening measures. Cancer prevalence has also been a major factor of concern for the global healthcare industry.

Market Challenges:

High Price of Products/Services Limiting Adoption of Clinical Biomarkers in Low-Income Countries: Despite a high opportunity for expansion in different regions, the need for high investment and infrastructure is the only reason restraining the market players from making investments. Expensive instruments are the major contributing factor to the high capital requirement. Therefore, the scale of capital investment required varies depending on the scale and abilities of the laboratory established. Though the global clinical biomarkers market possesses immense potential, the high capital investment requirement is hampering the expansion of global reach and thereby challenging the growth of the market globally.

Market Opportunities:

Technological Advancement in Biomarker Testing: Significant advancements have been achieved in biomarker detection technologies, leading to the development of various methods based on highly specific recognition biomarkers. Biomarker detection techniques encompass a range of approaches, including enzyme-linked immunosorbent assay (ELISA), gel electrophoresis, surface plasmon resonance (SPR), Mass-sensing BioCD protein array, surface-enhanced Raman spectroscopy (SERS), colorimetric assay, electrochemical assay, and fluorescence methods.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The global clinical biomarkers market has been segmented on the basis of various categories, such as offering, technology, clinical area, end user, and region. Segments such as by offering and by clinical area are then further subsegmented to ensure the comprehensiveness and thoroughness of the report.

Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments, at nearly 59% of the total developments in the clinical biomarkers market between January 2019 and December 2023. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.

Competitive Strategy: The global clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2022. A historical year analysis has been done for the period FY2019-FY2021. The market size has been estimated for FY2022 and projected for the period FY2023-FY2033.
  • The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of clinical biomarkers.
  • The market contribution of clinical biomarkers anticipated to be launched in the future has been calculated based on the historical analysis of the solutions.
  • Revenues of the companies have been referenced from their annual reports for FY2022 and FY2023. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
  • The market has been mapped based on the available clinical biomarker solutions. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in clinical biomarkers, including the market players offering centrifugation products and services. Resources such as specialists, scientists, marketing heads, researchers, CXOs, and manufacturing managers have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of the report's segmentation and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of the different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • World Health Organization (WHO), National Institute of Health, National Medical Product Administration (NMPA), Food and Drug Administration (FDA), National Institute of Health (NIH) and PubMed, among others.
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Databases such as MarkerDB, Global Online Biomarker Platform (GOBIOM) and Cancer Biomarkers database
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players of the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The product segment players leading the market captured around 76.59% of the market's presence as of 2022. Services, on the other hand, accounted for approximately 23.41% of the market presence in 2022.

Some prominent names established in this market are:

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ALCEN
  • Arsenal Capital Partners
  • Azenta Life Sciences
  • Becton, Dickinson and Company
  • BGI
  • bioMerieux S.A.
  • Bio-Rad Laboratories, Inc.
  • Broad Institute
  • Caris Life Sciences
  • CENTOGENE N.V.
  • Charles River Laboratories
  • Discovery Life Sciences (DLS)
  • Enzo Biochem Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • Novogene Co., Ltd.
  • Personalis Inc.
  • Q² Solutions
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc.

Table of Contents

Executive Summary

1. Market

  • 1.1. Product Definition
  • 1.2. Inclusion and Exclusion

2. Market Scope

  • 2.1. Key Questions Answered in the Report

3. Research Methodology

  • 3.1. Data Sources
    • 3.1.1. Primary Data Source
    • 3.1.2. Secondary Data Sources
      • 3.1.2.1. Open Sources
  • 3.2. Market Estimation Model
  • 3.3. Criteria for Company Profiling

4. Market Overview

  • 4.1. Introduction
  • 4.2. Clinical Biomarkers Approaches in Precision Medicine
  • 4.3. Market Size Potential for Clinical Biomarkers, 2022-2033
  • 4.4. COVID-19 Impact on Global Clinical Biomarkers Market
    • 4.4.1. COVID-19 Impact on Market Size
  • 4.5. Market Trends
    • 4.5.1. Integration of Artificial Intelligence in Biomarker Discovery
    • 4.5.2. Increasing Biomarkers Usage in Precision Medicine
    • 4.5.3. Technologies Being Used in Clinical Biomarker Testing
    • 4.5.4. Clinical Biomarker Discovery Making Early Disease Diagnosis Possible

5. Industry Insights

  • 5.1. Regulatory Framework
    • 5.1.1. Regulatory Framework in the U.S.
    • 5.1.2. FDA Regulations
    • 5.1.3. Biomarker Qualification: Evidentiary Framework Guidance for Industry and FDA Staff
    • 5.1.4. Regulatory Framework in the U.S. for Medical Devices
    • 5.1.5. Legal Requirements and Framework in Europe
      • 5.1.5.1. U.K.
      • 5.1.5.2. Germany
    • 5.1.6. Legal Requirements and Framework in Asia-Pacific
      • 5.1.6.1. China
      • 5.1.6.2. Japan
        • 5.1.6.2.1. Pharmaceuticals and Medical Devices Agency (PMDA)
  • 5.2. Patent Analysis
  • 5.3. Competitive Index (Unmet Needs and Innovations)
  • 5.4. Pain Points of Manufacturers

6. Competitive Insights

  • 6.1. Corporate Strategies
    • 6.1.1. Acquisitions
    • 6.1.2. Synergistic Activities
    • 6.1.3. Funding and Business Expansions
  • 6.2. Business Strategies
    • 6.2.1. Service/Product Launches
  • 6.3. Supply Chain Analysis
  • 6.4. Pricing Analysis
    • 6.4.1. Pricing Analysis (by Product)
    • 6.4.2. Pricing Analysis (by Testing Service)
  • 6.5. Market Share Analysis (by Product Manufacturer)
  • 6.6. Market Share Analysis (by Service Provider)

7. Market Dynamics

  • 7.1. Overview
  • 7.2. Impact Analysis
  • 7.3. Market Drivers
    • 7.3.1. Growing Demand for Clinical Biomarker Products
    • 7.3.2. Increase in Industrial Activity in Clinical Biomarker Landscape
    • 7.3.3. Environment Changes Provoking Swift Care and Diagnosis
  • 7.4. Market Challenges
    • 7.4.1. High Price of Products/Services Limiting Adoption of Clinical Biomarkers in Low-Income Countries
    • 7.4.2. Complex Regulatory Frameworks Delaying Approval of New Clinical Biomarkers Tests
    • 7.4.3. Difficulty in Identifying New Biomarkers
  • 7.5. Market Opportunities
    • 7.5.1. Technological Advancement in Biomarker Testing
    • 7.5.2. Increased Research Funding for Executing Research and Development Exercise
    • 7.5.3. Discovery of Novel Biomarkers Expanding Precision Medicine Horizons

8. Global Clinical Biomarkers Market, by Offering, $Billion, 2022-2033

  • 8.1. Overview
  • 8.2. Product
    • 8.2.1. Efficacy Biomarker
      • 8.2.1.1. Diagnostic Biomarker
      • 8.2.1.2. Predictive Biomarker
      • 8.2.1.3. Prognostic Biomarker
    • 8.2.2. Safety Biomarker
    • 8.2.3. Validation Biomarker
  • 8.3. Service
    • 8.3.1. Genomic Biomarker Service
    • 8.3.2. Tissue Biomarker Service
    • 8.3.3. Cell Service
    • 8.3.4. Proteomics Service

9. Global Clinical Biomarkers Market, by Technology, $Billion, 2022-2033

  • 9.1. Overview
  • 9.2. Next-Generation Sequencing (NGS)
  • 9.3. Polymerase Chain Reaction (PCR)
  • 9.4. Immunohistochemistry (IHC)
  • 9.5. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 9.6. Other Technologies

10. Global Clinical Biomarkers Market, by Clinical Area, $Billion, 2022-2033

  • 10.1. Overview
  • 10.2. Cancer Biomarker
    • 10.2.1. Breast Cancer Biomarker
    • 10.2.2. Lung Cancer Biomarker
    • 10.2.3. Colorectal Cancer Biomarker
    • 10.2.4. Prostate Cancer Biomarker
    • 10.2.5. Other
  • 10.3. Cardiac Biomarker
  • 10.4. Neurological Biomarker
  • 10.5. Infectious Disease Biomarker
  • 10.6. Non-Invasive Prenatal Testing
  • 10.7. Immunological Biomarker
  • 10.8. Other Clinical Areas

11. Global Clinical Biomarkers Market, by End User, $Billion, 2022-2033

  • 11.1. Overview
    • 11.1.1. Contract Research Organizations (CROs)
    • 11.1.2. Research and Academic Laboratories
    • 11.1.3. Diagnostic Centers
    • 11.1.4. Biopharmaceutical and Biotech Companies
    • 11.1.5. Other End Users

12. Region

  • 12.1. Overview
  • 12.2. North America
    • 12.2.1. U.S.
    • 12.2.2. Canada
  • 12.3. Europe
    • 12.3.1. Germany
    • 12.3.2. France
    • 12.3.3. U.K.
    • 12.3.4. Italy
    • 12.3.5. Spain
    • 12.3.6. Rest-of-Europe
  • 12.4. Asia-Pacific
    • 12.4.1. China
    • 12.4.2. India
    • 12.4.3. Japan
    • 12.4.4. South Korea
    • 12.4.5. Australia
    • 12.4.6. Rest-of-Asia-Pacific
  • 12.5. Latin America
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest-of-Latin America
  • 12.6. Rest-of-the-World

13. Market - Company Profiles

  • 13.1. Overview
  • 13.2. Abbott Laboratories
    • 13.2.1. Company Overview
    • 13.2.2. Role of Abbott Laboratories in the Global Clinical Biomarkers Market
    • 13.2.3. Corporate Strategies
      • 13.2.3.1. Product Launches
    • 13.2.4. Business Strategies
      • 13.2.4.1. Synergistic Activities
    • 13.2.5. Financials
    • 13.2.6. Analyst's Perspective
  • 13.3. Agilent Technologies, Inc.
    • 13.3.1. Company Overview
    • 13.3.2. Role of Agilent Technologies, Inc. in the Global Clinical Biomarkers Market
    • 13.3.3. Corporate Strategies
      • 13.3.3.1. Product Launches
    • 13.3.4. Financials
    • 13.3.5. Analyst's Perspective
  • 13.4. ALCEN
    • 13.4.1. Company Overview
    • 13.4.2. Role of ALCEN in the Global Clinical Biomarkers Market
    • 13.4.3. Analyst's Perspective
  • 13.5. Arsenal Capital Partners
    • 13.5.1. Company Overview
    • 13.5.2. Role of Arsenal Capital Partners in the Global Clinical Biomarkers Market
    • 13.5.3. Business Strategies
      • 13.5.3.1. Funding and Expansion
    • 13.5.4. Corporate Strategies
      • 13.5.4.1. Synergistic Activities
    • 13.5.5. Analyst's Perspective
  • 13.6. Azenta Life Sciences
    • 13.6.1. Company Overview
    • 13.6.2. Role of Azenta Life Sciences in the Global Clinical Biomarkers Market
    • 13.6.3. Business Strategies
      • 13.6.3.1. Acquisition
    • 13.6.1. Financials
    • 13.6.2. Analyst's Perspectives
  • 13.7. Becton, Dickinson and Company
    • 13.7.1. Company Overview
    • 13.7.2. Role of Becton, Dickinson and Company in the Global Clinical Biomarkers Market
    • 13.7.3. Financials
    • 13.7.4. Analyst's Perspective
  • 13.8. Bio-Rad Laboratories, Inc.
    • 13.8.1. Company Overview
    • 13.8.2. Role of Bio-Rad Laboratories, Inc. in the Global Clinical Biomarkers Market
    • 13.8.3. Financials
    • 13.8.4. Analyst's Perspective
  • 13.9. bioMerieux S.A.
    • 13.9.1. Company Overview
    • 13.9.2. Role of bioMerieux S.A. in the Global Clinical Biomarkers Market
    • 13.9.3. Corporate Strategies
      • 13.9.3.1. Funding and Expansion
      • 13.9.3.2. Product Launches
    • 13.9.4. Financials
    • 13.9.5. Analyst's Perspective
  • 13.1. BGI
    • 13.10.1. Company Overview
    • 13.10.2. Role of BGI in the Global Clinical Biomarkers Market
    • 13.10.3. Corporate Strategies
      • 13.10.3.1. Product Launch
    • 13.10.4. Analyst's Perspective
  • 13.11. Broad Institute
    • 13.11.1. Company Overview
    • 13.11.2. Role of Broad Institute in the Global Clinical Biomarkers Market
    • 13.11.3. Analyst's Perspective
  • 13.12. Charles River Laboratories
    • 13.12.1. Company Overview
    • 13.12.2. Role of Charles River Laboratories in the Global Clinical Biomarkers Market
    • 13.12.3. Financials
    • 13.12.4. Analyst's Perspective
  • 13.13. Caris Life Sciences
    • 13.13.1. Company Overview
    • 13.13.2. Role of Caris Life Sciences in the Global Clinical Biomarkers Market
    • 13.13.3. Analyst's Perspective
  • 13.14. CENTOGENE N.V.
    • 13.14.1. Company Overview
    • 13.14.2. Role of CENTOGENE N.V. in the Global Clinical Biomarkers Market
    • 13.14.3. Business Strategies
      • 13.14.3.1. Funding
    • 13.14.4. Corporate Strategies
      • 13.14.4.1. Synergistic Activities
    • 13.14.5. Financials
    • 13.14.6. Analyst's Perspective
  • 13.15. Discovery Life Sciences (DLS)
    • 13.15.1. Company Overview
    • 13.15.2. Role of Discovery Life Sciences in the Global Clinical Biomarkers Market
    • 13.15.3. Business Strategies
      • 13.15.3.1. Acquisition
    • 13.15.4. Analyst's Perspective
  • 13.16. Enzo Biochem Inc.
    • 13.16.1. Company Overview
    • 13.16.2. Role of Enzo Biochem Inc. in the Global Clinical Biomarkers Market
    • 13.16.3. Financials
    • 13.16.4. Analyst's Perspective
  • 13.17. Eurofins Scientific
    • 13.17.1. Company Overview
    • 13.17.2. Role of Eurofins Scientific in the Global Clinical Biomarkers Market
    • 13.17.3. Corporate Strategies
      • 13.17.3.1. Product Launches
    • 13.17.4. Financials
    • 13.17.5. Analyst's Perspective
  • 13.18. F. Hoffmann-La Roche Ltd
    • 13.18.1. Company Overview
    • 13.18.2. Role of F. Hoffmann-La Roche Ltd in the Global Clinical Biomarkers Market
    • 13.18.3. Business Strategies
      • 13.18.3.1. Product Launches
    • 13.18.4. Corporate Strategies
      • 13.18.4.1. Synergistic Activities
    • 13.18.5. Financials
    • 13.18.6. Analyst's Perspective
  • 13.19. Illumina, Inc.
    • 13.19.1. Company Overview
    • 13.19.2. Role of Illumina, Inc. in the Global Clinical Biomarkers Market
    • 13.19.3. Corporate Strategies
      • 13.19.3.1. Product Launches
    • 13.19.4. Financials
    • 13.19.5. Analyst's Perspective
  • 13.2. Myriad Genetics, Inc.
    • 13.20.1. Company Overview
    • 13.20.2. Role of Myriad Genetics, Inc. in the Global Clinical Biomarkers Market
    • 13.20.3. Business Strategies
      • 13.20.3.1. Product Launches
    • 13.20.4. Financials
    • 13.20.5. Analyst's Perspective
  • 13.21. NeoGenomics Laboratories
    • 13.21.1. Company Overview
    • 13.21.2. Role of NeoGenomics Laboratories in the Global Clinical Biomarkers Market
    • 13.21.3. Business Strategies
      • 13.21.3.1. Funding and Expansion
      • 13.21.3.2. Product Launches
    • 13.21.4. Corporate Strategies
      • 13.21.4.1. Synergistic Activities
    • 13.21.5. Financials
    • 13.21.6. Analyst's Perspective
  • 13.22. Novogene Co., Ltd.
    • 13.22.1. Company Overview
    • 13.22.2. Role of Novogene Co., Ltd. in the Global Clinical Biomarkers Market
    • 13.22.3. Analyst's Perspective
  • 13.23. Personalis Inc.
    • 13.23.1. Company Overview
    • 13.23.2. Role of Personalis Inc. in the Global Clinical Biomarkers Market
    • 13.23.3. Business Strategies
      • 13.23.3.1. Funding and Expansion
      • 13.23.3.2. Product Launches
    • 13.23.4. Corporate Strategies
      • 13.23.4.1. Synergistic Activities
    • 13.23.5. Financials
    • 13.23.6. Analyst's Perspective
  • 13.24. QIAGEN N.V.
    • 13.24.1. Company Overview
    • 13.24.2. Role of QIAGEN N.V. in the Global Clinical Biomarkers Market
    • 13.24.3. Corporate Strategies
      • 13.24.3.1. Product Launches
    • 13.24.4. Business Strategies
      • 13.24.4.1. Synergistic Activities
    • 13.24.5. Financials
    • 13.24.6. Analyst's Perspective
  • 13.25. Quest Diagnostics Incorporated
    • 13.25.1. Company Overview
    • 13.25.2. Role of Quest Diagnostics Incorporated in the Global Clinical Biomarkers Market
    • 13.25.3. Financials
    • 13.25.4. Analyst Perspective
  • 13.26. Q2. Solutions
    • 13.26.1. Company Overview
    • 13.26.2. Role of Q2 Solutions in the Global Clinical Biomarkers Market
    • 13.26.3. Business Strategies
      • 13.26.3.1. Funding and Expansion
    • 13.26.4. Corporate Strategies
      • 13.26.4.1. Synergistic Activities
    • 13.26.5. Analyst's Perspective
  • 13.27. Thermo Fisher Scientific Inc.
    • 13.27.1. Company Overview
    • 13.27.2. Role of Thermo Fisher Scientific Inc. in the Global Clinical Biomarkers Market
    • 13.27.3. Business Strategies
      • 13.27.3.1. Expansion and Funding
      • 13.27.3.2. Product Launches
    • 13.27.4. Corporate Strategies
      • 13.27.4.1. Synergistic Activities
    • 13.27.5. Financials
    • 13.27.6. Analyst's Perspective

List of Figures

  • Figure 1: Global Clinical Biomarkers Market Dynamics
  • Figure 2: Global Clinical Biomarkers Market (by Offering), $Billion, 2022 and 2033
  • Figure 3: Global Clinical Biomarkers Market (by Technology), $Billion, 2022 and 2033
  • Figure 4: Global Clinical Biomarkers Market (by Clinical Area), $Billion, 2022 and 2033
  • Figure 5: Global Clinical Biomarkers Market (by End User), $Billion, 2022 and 2033
  • Figure 6: Global Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
  • Figure 7: Global Clinical Biomarkers Market Research Methodology
  • Figure 8: Primary Research Methodology
  • Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 10: Top-Down Approach (Segment-Wise Analysis)
  • Figure 11: Biomarkers Used in Various Clinical Areas
  • Figure 12: Leading Segments of the Global Clinical Biomarkers Market, 2022 and 2033
  • Figure 13: Global Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 14: Impact of COVID-19 on Clinical Biomarkers Market
  • Figure 15: Usage of Artificial Intelligence (AI) in Biomarker Discovery
  • Figure 16: Use of Clinical Biomarkers in Personalized Medicine
  • Figure 17: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, % Share, 2010-2019
  • Figure 18: Responsibilities of the National Medical Products Administration (NMPA)
  • Figure 19: Unmet Needs and Innovations of Top Players
  • Figure 20: Pain Point, Impact, and Future Strategies for Manufacturers
  • Figure 21: Share of Synergistic Activities (by Company), January 2019-December 2023
  • Figure 22: Funding and Business Expansions (by Company), January 2019-December 2023
  • Figure 23: Service/Product Launches (by Key Companies), January 2019-December 2023
  • Figure 24: Clinical Biomarkers Supply Chain Analysis
  • Figure 25: Global Clinical Biomarkers Market (by Product Manufacturer), % Share, 2022
  • Figure 26: Global Clinical Biomarkers Market (by Service Provider), % Share, 2022
  • Figure 27: Role of Biomarkers in Cancer Care
  • Figure 28: History of Known Pandemics (100 AD to 2020)
  • Figure 29: Increasing Cancer Cases in U.S. with Percentage Increase, 2019 and 2022
  • Figure 30: Evidentiary Framework
  • Figure 31: Latest Technologies Seen in the Clinical Biomarkers Market and its Relevance
  • Figure 32: National Institute of Health (NIH) Funding, 2019-2022
  • Figure 33: Global Clinical Biomarkers Market (by Offering)
  • Figure 34: Share of Global Clinical Biomarkers Market (by Offering), $Billion, 2022 and 2033
  • Figure 35: Share of Global Clinical Biomarkers Market (by Product), $Billion, 2022 and 2033
  • Figure 36: Global Clinical Biomarkers Market (Product), $Billion, 2022-2033
  • Figure 37: Global Clinical Biomarkers Market (Efficacy Biomarker), $Billion, 2022-2033
  • Figure 38: Global Clinical Biomarkers Market (Diagnostic Biomarker), $Billion, 2022-2033
  • Figure 39: Role and Example of Predictive Biomarker
  • Figure 40: Global Clinical Biomarkers Market (Predictive Biomarker), $Billion, 2022-2033
  • Figure 41: Global Clinical Biomarkers Market (Prognostic Biomarker), $Billion, 2022-2033
  • Figure 42: Global Clinical Biomarkers Market (Safety Biomarker), $Billion, 2022-2033
  • Figure 43: Global Clinical Biomarkers Market (Validation Biomarker), $Billion, 2022-2033
  • Figure 44: Share of Global Clinical Biomarkers Market (by Service), $Billion, 2022 and 2033
  • Figure 45: Global Clinical Biomarkers Market (Service), $Billion, 2022-2033
  • Figure 46: Global Clinical Biomarkers Market (Genomic Biomarker Service), $Billion, 2022-2033
  • Figure 47: Global Clinical Biomarkers Market (Tissue Biomarker Service), $Billion, 2022-2033
  • Figure 48: Global Clinical Biomarkers Market (Cell Service), $Billion, 2022-2033
  • Figure 49: Global Clinical Biomarkers Market (Proteomics Service), $Billion, 2022-2033
  • Figure 50: Global Clinical Biomarkers Market (by Technology)
  • Figure 51: Global Clinical Biomarkers Market (by Technology), $Billion, 2022 and 2033
  • Figure 52: Benefits of NGS for Clinical Diagnostics and Biomarker Testing in Oncology
  • Figure 53: Global Clinical Biomarkers Market (Next-Generation Sequencing), $Billion, 2022-2033
  • Figure 54: Application of PCR
  • Figure 55: Global Clinical Biomarkers Market (Polymerase Chain Reaction), $Billion, 2022-2033
  • Figure 56: Global Clinical Biomarkers Market (Immunohistochemistry (IHC)), $Billion, 2022-2033
  • Figure 57: Global Clinical Biomarkers Market Enzyme-Linked Immunosorbent Assay (ELISA)), $Billion, 2022-2033
  • Figure 58: Global Clinical Biomarkers Market (Other Technologies), $Billion, 2022-2033
  • Figure 59: Cancers and their Biomarkers
  • Figure 60: Global Clinical Biomarkers Market (by Clinical Area)
  • Figure 61: Global Clinical Biomarkers Market (by Clinical Area), $Billion, 2022 and 2033
  • Figure 62: Global Clinical Biomarkers Market (Cancer Biomarker), $Billion, 2022-2033
  • Figure 63: Global Clinical Biomarkers Market (Breast Cancer Biomarker), $Billion, 2022-2033
  • Figure 64: Percentage of Non-Small Cell Lung Cancer (NSCLC) and its Biomarkers
  • Figure 65: Global Clinical Biomarkers Market (Lung Cancer Biomarker), $Billion, 2022-2033
  • Figure 66: Global Clinical Biomarkers Market (Colorectal Cancer Biomarker), $Billion, 2022-2033
  • Figure 67: Global Clinical Biomarkers Market (Prostate Cancer Biomarker), $Billion, 2022-2033
  • Figure 68: Global Clinical Biomarkers Market (Other), $Billion, 2022-2033
  • Figure 69: Global Clinical Biomarkers Market (Cardiac Biomarker), $Billion, 2022-2033
  • Figure 70: Global Clinical Biomarkers Market (Neurological Biomarker), $Billion, 2022-2033
  • Figure 71: Global Clinical Biomarkers Market (Infectious Disease Biomarker), $Billion, 2022-2033
  • Figure 72: Global Clinical Biomarkers Market Non-Invasive Prenatal Testing (NIPT)), $Billion, 2022-2033
  • Figure 73: Global Clinical Biomarkers Market (Immunological Biomarker), $Billion, 2022-2033
  • Figure 74: Global Clinical Biomarkers market (Other Clinical Areas), $Billion, 2022-2033
  • Figure 75: Global Clinical Biomarkers Market (by End User), $Billion, 2022 and 2033
  • Figure 76: Global Clinical Biomarkers Market (Contract Research Organizations (CROs)), $Billion, 2022-2033
  • Figure 77: Global Clinical Biomarkers Market (Research and Academic Laboratories), $Billion, 2022-2033
  • Figure 78: Global Clinical Biomarkers Market (Diagnostic Centers), $Billion, 2022-2033
  • Figure 79: Global Clinical Biomarkers Market (Biopharmaceutical and Biotech Companies), $Billion, 2022-2033
  • Figure 80: Global Clinical Biomarkers Market (Other End Users), $Billion, 2022-2033
  • Figure 81: Global Clinical Biomarkers Market Snapshot (by Region), $Billion, 2022-2033
  • Figure 82: Global Clinical Biomarkers Market (by Region), $Billion, 2022-2033
  • Figure 83: Global Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
  • Figure 84: North America Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 85: North America: Market Dynamics
  • Figure 86: North America Clinical Biomarkers Market (by Country), $Billion, 2022-2033
  • Figure 87: U.S. Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 88: Canada Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 89: Europe Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 90: Europe: Market Dynamics
  • Figure 91: Europe Clinical Biomarkers Market (by Country), $Billion, 2022-2033
  • Figure 92: Germany Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 93: Share of Cancer Cases in Germany, 2020
  • Figure 94: France Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 95: U.K. Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 96: Italy Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 97: Spain Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 98: Rest-of-Europe Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 99: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 100: Asia-Pacific Clinical Biomarkers Market (by Country), $Billion, 2022-2033
  • Figure 101: Asia-Pacific: Market Dynamics
  • Figure 102: China Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 103: India Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 104: Japan Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 105: South Korea Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 106: Australia Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 107: Rest-of-Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 108: Latin America Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 109: Latin America: Market Dynamics
  • Figure 110: Latin America Clinical Biomarkers Market (by Country), $Billion, 2022-2033
  • Figure 111: Brazil Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 112: Mexico Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 113: Rest-of-Latin America Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 114: Rest-of-the-World Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 115: Total Number of Companies Profiled
  • Figure 116: Abbott Laboratories: Product Portfolio
  • Figure 117: Abbott Laboratories: Overall Financials, $Million, 2020-2022
  • Figure 118: Abbott Laboratories: Revenue (by Segment), $Million, 2020-2022
  • Figure 119: Abbott Laboratories: R&D Expenditure, $Million, 2020-2022
  • Figure 120: Agilent Technologies, Inc.: Product Portfolio
  • Figure 121: Agilent Technologies, Inc.: Overall Financials, $Million, 2021-2023
  • Figure 122: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2021-2023
  • Figure 123: ALCEN: Service Portfolio
  • Figure 124: Arsenal Capital Partners: Services Portfolio
  • Figure 125: Azenta Life Sciences: Service Portfolio
  • Figure 126: Azenta Life Sciences: Overall Financials, $Million, 2021-2023
  • Figure 127: Becton, Dickinson and Company: Product Portfolio
  • Figure 128: Becton, Dickinson and Company: Overall Financials, $Million, 2021-2023
  • Figure 129: Becton, Dickinson and Company: Revenue (by Segment), $Million, 2021-2023
  • Figure 130: Becton, Dickinson and Company: Revenue (by Region), $Million, 2021-2023
  • Figure 131: Becton, Dickinson and Company: R&D Expenditure, $Million, 2021-2023
  • Figure 132: Bio-Rad Laboratories, Inc.: Product Portfolio
  • Figure 133: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2020-2022
  • Figure 134: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2020-2022
  • Figure 135: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2020-2022
  • Figure 136: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
  • Figure 137: bioMerieux S.A.: Product Portfolio
  • Figure 138: bioMerieux S.A.: Overall Financials, $Million, 2020-2022
  • Figure 139: bioMerieux S.A.: Revenue (by Segment), $Million, 2020-2022
  • Figure 140: BGI: Service Portfolio
  • Figure 141: Broad Institute: Service Portfolio
  • Figure 142: Charles River Laboratories: Service Portfolio
  • Figure 143: Charles River Laboratories: Overall Financials, $Million, 2020-2022
  • Figure 144: Charles River Laboratories: Revenue (by Segment), $Million, 2020-2022
  • Figure 145: Charles River Laboratories.: Revenue (by Region), $Million, 2020-2022
  • Figure 146: Caris Life Sciences: Service Portfolio
  • Figure 147: CENTOGENE N.V.: Service Portfolio
  • Figure 148: CENTOGENE N.V.: Overall Financials, $Million, 2020-2022
  • Figure 149: Discovery Life Sciences: Service Portfolio
  • Figure 150: Enzo Biochem Inc.: Product Portfolio
  • Figure 151: Enzo Biochem Inc.: Overall Financials, $Million, 2020-2022
  • Figure 152: Enzo Biochem Inc.: R&D Expenditure, 2020-2022
  • Figure 153: Eurofins Scientific: Service Portfolio
  • Figure 154: Eurofins Scientific: Overall Financials, $Million, 2020-2022
  • Figure 155: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 156: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
  • Figure 157: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
  • Figure 158: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
  • Figure 159: Illumina, Inc.: Product Portfolio
  • Figure 160: Illumina, Inc.: Overall Financials, $Million, 2020-2022
  • Figure 161: Illumina, Inc.: Revenue (by Segment), $Million, 2020-2022
  • Figure 162: Illumina, Inc.: Revenue (by Region), $Million, 2020-2022
  • Figure 163: Illumina, Inc.: R&D Expenditure, $Million, 2020-2022
  • Figure 164: Myriad Genetics, Inc.: Service Portfolio
  • Figure 165: Myriad Genetics, Inc.: Overall Financials, $Million, 2020-2022
  • Figure 166: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2020-2022
  • Figure 167: NeoGenomics Laboratories: Service Portfolio
  • Figure 168: NeoGenomics Laboratories: Overall Financials, $Million 2020-2022
  • Figure 169: NeoGenomics Laboratories: Revenue (by Segment), 2020-2022
  • Figure 170: NeoGenomics Laboratories: R&D Expenditure, 2020-2022
  • Figure 171: Novogene Co., Ltd.: Service Portfolio
  • Figure 172: Personalis Inc.: Service Portfolio
  • Figure 173: Personalis Inc.: Overall Financials, $Million, 2020-2022
  • Figure 174: Personalis Inc.: R&D Expenditure, $Million, 2020-2022
  • Figure 175: QIAGEN N.V.: Product Portfolio
  • Figure 176: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
  • Figure 177: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
  • Figure 178: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
  • Figure 179: QIAGEN N.V.: R&D Expenditure, $Million, 20202022
  • Figure 180: Quest Diagnostics Incorporated, Inc.: Service Portfolio
  • Figure 181: Quest Diagnostics Incorporated: Overall Financials, $Million, 2020-2022
  • Figure 182: Quest Diagnostics Incorporated.: Revenue (by Segment), $Million, 2020-2022
  • Figure 183: Q2 Solutions: Service Portfolio
  • Figure 184: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 185: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
  • Figure 186: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: COVID-19 Impact on Global Clinical Biomarkers Market, 2020-2033
  • Table 2: List of Product/Service Offered and its Technology
  • Table 3: Global Clinical Biomarkers Market: Key Players Patent Portfolio
  • Table 4: Key Player Initiatives and Their Impact
  • Table 5: Pricing List of Product/Service
  • Table 6: List of Biomarker Qualification Submissions for FDA Approval
  • Table 7: Example of Efficacy Biomarker
  • Table 8: Examples of Diagnostic Biomarker
  • Table 9: Examples of Prognostic Biomarker
  • Table 10: Examples of Safety Biomarker
  • Table 11: Example of Clinical Biomarker Service
  • Table 12: Next-Generation Sequencing-Based Clinical Biomarker Products
  • Table 13: Polymerase Chain Reaction-Based Clinical Biomarker Products
  • Table 14: Immunohistochemistry (IHC)-Based Clinical Biomarker Products
  • Table 15: ELISA-Based Clinical Biomarker Products
  • Table 16: Companies Offering Other Technologies-Based Products
  • Table 17: Example of Cancer Biomarker
  • Table 18: Example of Cardiac Biomarker
  • Table 19: Example of Neurological Biomarker
  • Table 20: Examples of Infectious Disease Biomarker
  • Table 21: Estimated Cancer Deaths in California, 2022